Majeed Muhammed, Nagabhushanam Kalyanam, Natarajan Sankaran, Sivakumar Arumugam, Eshuis-de Ruiter Talitha, Booij-Veurink Janine, de Vries Ynte P, Ali Furqan
Sami Labs Limited, 19/1, 19/2, First Main, Second Phase, Peenya Industrial Area, Bangalore, 560 058, Karnataka, India.
Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ, 08520, USA.
World J Microbiol Biotechnol. 2016 Apr;32(4):60. doi: 10.1007/s11274-016-2027-2. Epub 2016 Feb 29.
Commercial probiotics preparation containing Bacillus coagulans have been sold in the market for several decades. Due to its high intra-species genomic diversity, it is very likely that B. coagulans strain may alter in different ways over multiple years of production. Therefore, the present study focuses to evaluate the genetic consistency and probiotic potential of B. coagulans MTCC 5856. Phenotypic and genotypic techniques including biochemical profiling, 16S rRNA sequencing, GTG 5″, BOX PCR fingerprinting, and Multi-Locus-Sequence typing (MLST) were carried out to evaluate the identity and consistency of the B. coagulans MTCC 5856. Further, in vitro probiotic potential, safety and stability at ambient temperature conditions of B. coagulans MTCC 5856 were evaluated. All the samples were identified as B. coagulans by biochemical profiling and 16S rRNA sequencing. GTG 5″, BOX PCR fingerprints and MLST studies revealed that the same strain was present over 3 years of commercial production. B. coagulans MTCC 5856 showed resistance to gastric acid, bile salt and exhibited antimicrobial activity in in-vitro studies. Additionally, B. coagulans MTCC 5856 was found to be non-mutagenic, non-cytotoxic, negative for enterotoxin genes and stable at ambient temperature (25 ± 2 °C) for 36 months. The data of the study verified that the same strain of B. coagulans MTCC 5856 was present in commercial preparation over multiple years of production.
含有凝结芽孢杆菌的商业益生菌制剂已在市场上销售了几十年。由于其种内基因组多样性高,凝结芽孢杆菌菌株很可能在多年生产过程中以不同方式发生变化。因此,本研究着重评估凝结芽孢杆菌MTCC 5856的遗传一致性和益生菌潜力。采用了包括生化分析、16S rRNA测序、GTG 5″、BOX PCR指纹图谱和多位点序列分型(MLST)在内的表型和基因型技术,以评估凝结芽孢杆菌MTCC 5856的同一性和一致性。此外,还评估了凝结芽孢杆菌MTCC 5856在体外的益生菌潜力、安全性以及在环境温度条件下的稳定性。通过生化分析和16S rRNA测序,所有样本均被鉴定为凝结芽孢杆菌。GTG 5″、BOX PCR指纹图谱和MLST研究表明,在3年的商业生产中存在同一菌株。凝结芽孢杆菌MTCC 5856在体外研究中表现出对胃酸、胆汁盐的抗性并具有抗菌活性。此外,发现凝结芽孢杆菌MTCC 5856无致突变性、无细胞毒性,肠毒素基因呈阴性,且在环境温度(25±2°C)下36个月稳定。该研究数据证实,在多年生产的商业制剂中存在同一菌株的凝结芽孢杆菌MTCC 5856。